A Phase I Dose-Escalation Study To Determine The Safety, Pharmacokinetics, And Pharmacodynamics Of BMS-354825 [dasatinib] In The Treatment Of Patients With Chronic Phase Chronic Myelogenous Leukemia Who Have Hematologic Resistance To Imatinib Mesylate (Gleevec)

Trial Profile

A Phase I Dose-Escalation Study To Determine The Safety, Pharmacokinetics, And Pharmacodynamics Of BMS-354825 [dasatinib] In The Treatment Of Patients With Chronic Phase Chronic Myelogenous Leukemia Who Have Hematologic Resistance To Imatinib Mesylate (Gleevec)

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Acute lymphoblastic leukaemia; Chronic myeloid leukaemia
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 01 Aug 2017 Results evaluating cardiovascular ischaemic event rates in dasatinib treated patients using patient data from NCT00103701, NCT00101647, NCT00101816, NCT00101660, NCT00101595, NCT00103844, NCT00123474, NCT00123487, NCT00481247, NCT00529763, NCT01357655, NCT00744497 trials and and comparing it with external reference populations published in the Annals of Hematology
    • 03 Aug 2012 Additional lead trial center and investigator identified as reported by ClinicalTrials.gov.
    • 03 Aug 2012 Additional lead trial center and investigator identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top